Given the favorable data for the FAST and FAST Forward trials, can we consider those ultra-hypofractionated whole breast radiation schemes to be standard of care for early stage breast cancer?

Topics: Breast Cancer • Radiation Oncology • Medical Oncology

Answer from: Radiation Oncologist at Academic Institution

With respect to FAST (28.5 Gy in 5 fx in 5 weeks), can be considered based on 10-year data (https://www.astro.org/ASTRO/media/ASTRO/Meetings%20and%20Education/PDFs/AM18/LBA18.pdf). Local control rates were low in all arms but in general, I limit this to patients who can't do standard hypofractionate...

Comments

Radiation Oncologist at Varian Medical Systems/Allegheny health network
We do offer for 60 and above low-risk disease who ...

Radiation Oncologist at Lake Huron Medical Center
@Chirag S. Shah - do you think the FAST-Forward st...

Radiation Oncologist at Cleveland Clinic
It's a great question, @Simul Parikh. In terms of ...

Answer from: Radiation Oncologist at Academic Institution

While there is only 5-year data, I am starting to use FAST-Forward in selected patients with significant transportation or COVID issues, and in whom I don't expect challenges achieving dose homogeneity with a 3D treatment plan. In the first few we've treated - I have followed weekly after treatment ...

Related Questions